Document Detail

Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro.
MedLine Citation:
PMID:  22314264     Owner:  NLM     Status:  Publisher    
Lobaplatin as a single agent and in combination with tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is investigated in in-vitro models of p53-negative triple-negative breast cancers (TNBCs) and compared with a model of oestrogen receptor-positive p53-positive breast cancer. In addition, the induction of programmed cell death by lobaplatin is further explored. By using cell viability assays and western blotting, the cytotoxic effects of lobaplatin alone and in combination with TRAIL are compared with cisplatin in HCC 1806, HCC 1937, and MCF 7 cells. The multicaspase inhibitor z-VAD-fmk and necrostatin, an inhibitor of necroptosis, are used to demonstrate the mechanism of cell death caused by lobaplatin. Lobaplatin displayed antitumour activity in all three cell lines, which increased time dependently. Cotreatment of lobaplatin and TRAIL induced an increase in cytotoxicity by 30-50% in the different cell lines. The pan-caspase inhibitor z-VAD-fmk as well as necrostatin could weaken but not abolish the cytotoxic effect of lobaplatin and cisplatin. Lobaplatin showed substantial cytotoxic effects in two in-vitro models of p53-mutated TNBC. Cotreatment with TRAIL and platinum agents resulted in increased antitumour activity in the TNBC cell lines investigated. Cell death subsequent to treatment with cisplatin and lobaplatin occurred because of apoptosis. However, caspase-independent mechanisms of programmed cell death were also involved. It was also demonstrated that platinum compounds could induce necroptosis, although to a minor extent.
Jörg B Engel; Theresa Martens; Jens C Hahne; Sebastian F M Häusler; Mathias Krockenberger; Sabine Segerer; Antonia Djakovic; Susanne Meyer; Johannes Dietl; Jörg Wischhusen; Arnd Honig
Related Documents :
1327854 - Regulation of cell growth and motility by hepatocyte growth factor and receptor express...
7513514 - Cell proliferation status, cytokine action and protein tyrosine phosphorylation modulat...
4929864 - Impaired transduction of r213 and its recovery by a homologous resident r factor.
8149584 - Regulation of cell division and rod differentiation in the teleost retina.
9351704 - Expression of two neuronal markers, growth-associated protein 43 and neuron-specific en...
16657924 - Movement of c-labeled assimilates into kernels of zea mays l: i. pattern and rate of su...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-5
Journal Detail:
Title:  Anti-cancer drugs     Volume:  -     ISSN:  1473-5741     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100823     Medline TA:  Anticancer Drugs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Obstetrics and Gynecology, University of Würzburg, Würzburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Efficacy and Safety of Dextromethorphan/Quinidine at Two Dosage Levels for Diabetic Neuropathic Pain...
Next Document:  Noxa/Mcl-1 balance influences the effect of the proteasome inhibitor MG-132 in combination with anti...